Can a Urine Cannabinoid Screen Predict Cannabis Withdrawal Severity? What 78 Inpatients Showed

Why the answer depends on what the urine test measures

It is tempting to treat a higher laboratory number as a larger current drug effect. This study is a useful example of why that shortcut fails. Its central specimen was urine and its routine instrument was a semiquantitative cannabinoid immunoassay. Such a test responds to immunochemically recognized cannabinoids or metabolites in the specimen. It does not continuously measure THC at a brain receptor and does not itself determine whether the patient is clinically impaired or experiencing a given withdrawal symptom.

The investigators described the reported immunoassay results for convenience as urinary “THC-COOH levels.” That terminology requires care. The assay could respond to several related cannabinoids, including THC, hydroxy metabolites, carboxy metabolites and cannabidiol. A reported THC-COOH-equivalent reading is therefore not analytically identical to a specific quantitative, chromatographically confirmed concentration of only 11-nor-9-carboxy-Δ9-THC. Even for a specific confirmed urine metabolite, excretion, hydration and time since prior exposure can alter concentration without tracking moment-to-moment behavioral status.

The research question was whether measurements from an accessible clinical urine-testing process tracked withdrawal severity during treatment. It was not a validation of a driving-under-the-influence threshold, a urine-based clock for cannabis consumption, or a substitute for an independent patient examination.

Who was studied: 78 treatment-seeking adults, not 78 random cannabis users

The prospective study recruited in an inpatient psychiatric detoxification program in Essen, Germany, between 2008 and 2014. Eligible adults had a positive admission urine cannabinoid screen, an established cannabis-dependence diagnosis, daily or near-daily inhaled cannabis use in the preceding six months, and reported cannabis consumption during the 24 hours before admission. The protocol excluded recent use of other psychotropic drugs apart from tobacco and active medical or psychiatric illness requiring separate treatment. These enrollment conditions selected a particular clinical population rather than a representative group of everyone who uses cannabis.

There were 78 individual participants: 60 men and 18 women. Mean age was 26.4 years (SD 7.0), with an age range of 18–51 years. The study scheduled assessments over as many as 24 inpatient days, with sampling at admission, the following day and then roughly every other day. Some participants left before day 24 because their clinical condition had improved; nine discontinued the program prematurely. Thus, later-day observations came from progressively fewer people. Repeated urine samples should not be counted as additional independent patients.

The average admission-to-discharge inpatient stay was 14.6 days (SD 6.5), and 69 of the 78 participants were discharged in the planned manner. Withdrawal care included psychosocial treatment and optional symptom-directed medications. This is an observational study of treated patients, not a randomized trial assigning cannabis exposure, detoxification length, or urine cannabinoid concentration.

What the clinicians recorded alongside the laboratory findings

Researchers evaluated symptoms with a modified Marijuana Withdrawal Checklist (MWC), an interviewer-administered symptom instrument, and assessed global clinical illness severity with the Clinical Global Impression—Severity (CGI-S) scale. The checklist included emotional and physical complaints associated with withdrawal, such as irritability, anxiety, restlessness, disturbed sleep, appetite change, headache, sweating and nausea. Symptoms are clinical reports and ratings, not chemical analytes.

The investigators paired successive urine measurements with symptom assessments and analyzed their association using repeated-measures correlation and multilevel models that accounted for multiple observations from the same person. These methods were intended to avoid the naive error of pretending every specimen was an independent human subject. They do not, by themselves, remove selection bias, the effects of medications given during treatment, or the changing composition of the patients still hospitalized late in the study.

The actual assay, matrix, calibration and normalization

The clinical measurement used a DRI cannabinoid enzyme immunoassay on a Beckman Coulter AU 400 chemistry analyzer. The authors specified a 200 ng/mL THC-COOH calibrator, a reported assay response range of 0–200 ng/mL and a 50 ng/mL cutoff. These are calibration and screening characteristics of the immunoassay; they are not a demonstration that an individual patient’s urine contained exactly that amount of a single chemically isolated THC metabolite.

Because a urine specimen’s concentration depends in part on its water content, the team also calculated a creatinine-normalized cannabinoid result from the measured urine creatinine. They separately examined BMI-normalized values as a rough exploration of body-composition effects. Neither normalization converts urine to whole blood. Urinary creatinine itself varies with physiology and collection circumstances, while BMI does not directly quantify adipose cannabinoid stores.

The urine series was the principal scientific measurement. In selected suspected-relapse situations, investigators described additional blood THC-OH gas chromatography–mass spectrometry as a confirmation step for protocol exclusions. That selective clinical measure was not a universal, paired venous whole-blood THC assay for all 78 people, and those selected blood findings cannot be substituted for the urine-based study association.

For general interpretation of different biological specimens, the separately published biological matrices guide explains why urine, serum, plasma and whole blood answer different analytical questions. The published confirmatory testing guide also distinguishes presumptive immunoassay reactivity from compound-specific confirmation.

Table 1: What the 78-person study actually measured

The main result: urine reactivity tracked symptoms, but weakly at the individual level

Across repeated observations, the association between raw urine assay readings and MWC symptom scores was r = 0.248, with a reported 95% confidence interval of 0.152 to 0.339 and p < 0.001. The analogous correlation after BMI normalization was r = 0.249 (95% CI 0.154–0.341; p < 0.001). A low p-value here indicates evidence of a nonzero population-level association in the fitted longitudinal analysis; it does not mean the urine number correctly determines a given person’s clinical state.

When normalized for urine creatinine, the overall association was r = 0.096, 95% CI −0.004 to 0.195, p = 0.059. This was not statistically significant under the paper’s p < 0.05 criterion. The shift from a significant raw assay correlation to a nonsignificant creatinine-normalized correlation is crucial for interpreting any proposed urine-based predictor. Some apparent relationship may be sensitive to the way hydration and specimen concentration are handled.

In adjusted multilevel models, the authors reported positive associations between MWC scores and the different immunoassay-derived indices, including creatinine-normalized values in a model sensitive to the dose of gabapentin used for symptom treatment. Because clinicians could provide medication when symptoms were distressing, medication use is entangled with clinical severity and cannot be read as a randomized experimental treatment effect. An association after adjustment does not replace a prospectively validated prediction equation.

Higher initial withdrawal scores identified a narrower significant subgroup

Among the 21 people whose admission MWC score was above 11, the creatinine-normalized urine measure did correlate with serial MWC scores: r = 0.247, 95% CI 0.094–0.390, p = 0.002. The multilevel association also remained statistically significant in this subgroup, with regression coefficient b = 0.011, 95% CI 0.003–0.019, p = 0.006.

By contrast, the 46-person lower-admission-score subgroup did not show this relationship: r = −0.043, 95% CI −0.173 to 0.088, p = 0.519. The corresponding adjusted coefficient, b = 0.0004, had a confidence interval crossing zero and p = 0.891. These two explicitly reported subgroup denominators should not be silently rounded up to the full 78-person cohort; the analyses involved different available observations.

The study supports a cautious interpretation: a urine result may be an auxiliary longitudinal signal in some hospitalized patients already known to have severe withdrawal. It does not supply a universal cutoff that prospectively classifies any untreated patient as experiencing mild, moderate or severe withdrawal. Neither does a higher subgroup correlation automatically demonstrate a formally tested between-subgroup interaction or accurate patient-level diagnosis.

Table 2: Positive and nonsignificant study outcomes side by side

What the day-by-day graph does—and does not—show

The plotted urine signal and symptom ratings generally declined during detoxification. However, the apparent upturn between days 16 and 22 occurred as participants with less severe symptoms were discharged and fewer, comparatively sicker people remained under observation. This is a changing-cohort composition effect, not a documented pharmacological rebound in every participant on day 16.

Figure 1 in the original paper shows decreasing numbers of observations as the program proceeds. A simple graph of the average remaining-patient urine result can therefore move upward even when earlier discharged individuals are improving. Any attempt to interpret the late-day line as a biological rule for a particular claimant would need a complete person-level trajectory and a model of missingness and discharge selection.

The authors reported a negative time coefficient for MWC severity in an adjusted model, b = −1.078 points per successive assessment (95% CI −1.873 to −0.284; p = 0.009). The model also reported declining unnormalized urine cannabinoid results over visits, b = −13.562 (95% CI −22.492 to −4.632; p = 0.003). These coefficients describe fitted average changes per observation in this treatment cohort, not a fixed pharmacokinetic clearance rate or an estimate of the amount of THC eliminated from whole blood.

Sex-related findings require separate scrutiny

The paper found slower decline in some urine cannabinoid indices among women and described longer symptom courses among those retained late in treatment. The model for raw urine levels reported a time-by-sex interaction b = −4.549 (95% CI −8.721 to −0.377; p = 0.035), interpreted by the authors as faster decline among men. A BMI-adjusted model also yielded a time-by-sex interaction. These observations should be weighed against the uneven enrollment: only 18 women versus 60 men.

Sex in this study was not randomized, admission characteristics were not equivalent to all potential hormonal or medication exposures, and menstrual phase was not controlled. BMI was available for 73 participants and does not precisely measure fat distribution. The small subgroup and differential discharge patterns constrain any general claim that biological sex alone determines the duration of excretion, the severity of withdrawal, or how an individual urine result should be interpreted.

Why the urine result cannot prove recent consumption or impairment

Urinary cannabinoid immunoreactivity primarily informs an excretion and screening question. It does not indicate a particular contemporaneous whole-blood THC concentration, receptor occupancy, or the moment of last exposure. The participant’s self-reported use within 24 hours before admission was an eligibility criterion, not a time-of-use determination inferred from the immunoassay value.

Withdrawal itself occurs as a clinical syndrome after reduction or cessation in a person with established prior use. It is conceptually different from acute intoxication. A patient may report substantial withdrawal while urine remains positive, and a positive urine screen may occur without observable acute impairment. Conversely, a urine result near the study’s screening cutoff is not sufficient to rule out withdrawal or establish safe performance of an attention or driving task.

No participants underwent a validated simulated-driving trial, standardized roadside sobriety testing, or an accident reconstruction as part of this research. No sensitivity, specificity, likelihood ratio or independently replicated classifier was supplied for determining a person’s withdrawal severity from one urine reading. Transferring its regression coefficient to a legal question about actual behavior requires validation that this study did not provide.

How an expert can use the research without overstating it

In litigation involving drug testing, treatment records or disputed symptoms, the study can help identify competing interpretations rather than supply a shortcut to a conclusion. The first inquiry is the exact analytical identity of the urine result: immunoassay reactivity, a creatinine-normalized value, or chromatographically confirmed THC-COOH. Next come urine collection time and integrity, calibration, the tested range, the longitudinal trend, and whether treatment medications or altered urine dilution plausibly affect comparisons.

Any symptom opinion should separately consider contemporaneous patient reports, clinician observations, coexisting medical or psychiatric findings, treatment interventions and the completeness of follow-up. If the question is drugged driving, actual behavioral evidence, appropriate specimen analysis and the relevant event chronology become critical; the existence of a urine cannabinoid-positive finding alone cannot make that determination.

The site’s published specimen-collection guide addresses the record needed to interpret time, collection conditions and specimen integrity. These general principles do not replace review of this study’s complete methods or an individual case file.

Seven frequently asked questions

1. Does a higher urine THC-COOH-equivalent result mean more severe withdrawal?

Not necessarily for an individual. Across this inpatient cohort, raw semiquantitative urine cannabinoid readings correlated modestly with withdrawal ratings (r = 0.248), but the relationship weakened and was nonsignificant after creatinine normalization across the full study. One number is not a validated severity diagnosis.

2. Was the routine urine test a GC–MS-confirmed quantitative THC-COOH assay?

No. The routine serial measure was a semiquantitative cannabinoid immunoassay, calibrated and reported in THC-COOH-equivalent terms despite potential reactivity to related compounds. Selected suspected-relapse assessments used additional blood testing; they do not turn every urine screening number into compound-specific mass-spectrometric confirmation.

3. Why did creatinine normalization matter?

Urine water content changes the concentration of substances in a specimen. Creatinine normalization tries to account for differing dilution, though creatinine has its own biological variability. In this study the overall r decreased from 0.248 for raw assay readings to 0.096 for creatinine-adjusted values, with p = 0.059.

4. Did any subgroup show a significant adjusted-urine association?

Yes. Among 21 people with higher MWC scores at admission, serial creatinine-adjusted results correlated with symptom ratings (r = 0.247; p = 0.002). The reported 46-person lower-severity group did not (r = −0.043; p = 0.519). The study did not provide a validated individual prediction threshold.

5. Why did the graph seem worse after about day 16?

Many patients improving earlier had already left treatment. The later average therefore represented a smaller and less representative set of continuing inpatients. A rise in the average of those remaining is not proof that every person’s symptoms or urine concentration rebounded.

6. Can the study estimate the last cannabis-use time or determine intoxication?

No. Eligibility required a report of recent use, but this was not validated from urine concentration. The analysis addressed serial withdrawal symptoms in a selected abstinence-treatment setting. It did not establish a blood THC value, time-since-use estimate, current intoxication or individual psychomotor impairment.

7. Is the reported association enough to guide discharge or a forensic opinion by itself?

No. Clinicians used broader assessment and treatment response; discharge altered who remained in later averages. A forensic opinion should review the original assay methodology, the complete clinical record and any independent behavior or event-specific evidence. This research can inform context but does not independently settle a case.

Bottom line and original primary citation

In 78 selected adults undergoing inpatient cannabis detoxification, serial semiquantitative urine cannabinoid immunoassay readings showed a modest association with clinical withdrawal ratings, while the full-sample creatinine-adjusted correlation was not significant. The more severe admission subgroup yielded a significant adjusted-urine association. All three statements can be true because they refer to different specimen transformations and analytic groups. None establishes an individually accurate withdrawal prediction, a measure of circulating THC, driving impairment, or the cause of a particular person’s conduct.

Primary study: Claus BB, Specka M, McAnally H, Scherbaum N, Schifano F, Bonnet U. Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor? Frontiers in Psychiatry. 2020;11:598150. https://doi.org/10.3389/fpsyt.2020.598150.